Osanetant by Acer Therapeutics for Vasomotor Symptoms of Menopause (Hot Flashes): Likelihood of Approval

Osanetant is under clinical development by Acer Therapeutics and currently in Phase II for Vasomotor Symptoms of Menopause (Hot Flashes). According to GlobalData, Phase II drugs for Vasomotor Symptoms of Menopause (Hot Flashes) have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Osanetant’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Osanetant overview

Osanetant (ACER-801) is under development for the treatment of  induced vasomotor symptoms, acute stress disorder, prostate cancer and post-traumatic stress disorder. The drug candidate is administered by oral route and acts by targeting NK3 receptor. It was also under development for the treatment of depression, neuroendocrine disorders and schizophrenia.

Acer Therapeutics overview

Acer Therapeutics (Acer), is a Pharmaceutical company. It offers commercialize therapies for patients with serious rare diseases. Its pipeline product portfolio include EDSIVO, for the treatment of vascular ehlers-danlos syndrome; ACER-001, a taste-masked, immediate release formulation of sodium phenyl butyrate for urea cycle disorders (UCD’s) and maple syrup urine disease (MSUD); osanetant, a neurokinin 3 receptor antagonist against induced vasomotor symptoms and emetine for infectious diseases. Acer uses T-cell technology platform for the development of patient-specific T-cell therapies. The company operates manufacturing facility, and research and development facilities in the US and Canada. Acer is headquartered in Newton, Massachusetts, the US.

For a complete picture of Osanetant’s drug-specific PTSR and LoA scores, buy the report here.